Mensing S - Search Results

1

Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).

Powderly J, Spira A, Kondo S, Doi T, Luke JJ, Rasco D, Gao B, Tanner M, Cassier PA, Gazzah A, Italiano A, Tosi D, Afar DE, Parikh A, Engelhardt B, Englert S, Lambert SL, Kasichayanula S, Mensing S, Menon R, Vosganian G, Tolcher A. Powderly J, et al. Among authors: mensing s. Clin Transl Sci. 2021 Jan;14(1):277-287. doi: 10.1111/cts.12855. Epub 2020 Dec 26. Clin Transl Sci. 2021. PMID: 32770720 Free PMC article. Clinical Trial.

2

Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies.

Mensing S, Polepally AR, König D, Khatri A, Liu W, Podsadecki TJ, Awni WM, Menon RM, Dutta S. Mensing S, et al. AAPS J. 2016 Jan;18(1):270-80. doi: 10.1208/s12248-015-9846-1. Epub 2015 Nov 23. AAPS J. 2016. PMID: 26597291 Free PMC article.

3

Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.

Polepally AR, Mensing S, Khatri A, Beck D, Liu W, Awni WM, Menon RM, Dutta S. Polepally AR, et al. Among authors: mensing s. Clin Pharmacokinet. 2016 Sep;55(9):1091-101. doi: 10.1007/s40262-016-0385-4. Clin Pharmacokinet. 2016. PMID: 27000758 Clinical Trial.

4

Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.

Gopalakrishnan S, Khatri A, Mensing S, Redman R, Menon R, Zha J. Gopalakrishnan S, et al. Among authors: mensing s. Adv Ther. 2016 Apr;33(4):670-83. doi: 10.1007/s12325-016-0320-y. Epub 2016 Mar 21. Adv Ther. 2016. PMID: 27084721 Clinical Trial.

5

Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.

Khatri A, Mensing S, Podsadecki T, Awni W, Menon R, Dutta S. Khatri A, et al. Among authors: mensing s. Clin Drug Investig. 2016 Aug;36(8):625-35. doi: 10.1007/s40261-016-0407-x. Clin Drug Investig. 2016. PMID: 27153823 Clinical Trial.

6

Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.

Polepally AR, Badri PS, Eckert D, Mensing S, Menon RM. Polepally AR, et al. Among authors: mensing s. Eur J Drug Metab Pharmacokinet. 2017 Apr;42(2):333-339. doi: 10.1007/s13318-016-0341-6. Eur J Drug Metab Pharmacokinet. 2017. PMID: 27165046

7

Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.

Gopalakrishnan SM, Polepally AR, Mensing S, Khatri A, Menon RM. Gopalakrishnan SM, et al. Among authors: mensing s. Clin Pharmacokinet. 2017 Jan;56(1):1-10. doi: 10.1007/s40262-016-0423-2. Clin Pharmacokinet. 2017. PMID: 27314261 Clinical Trial.

8

Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trials.

Polepally AR, Badri PS, Parikh A, Rodrigues L Jr, Da Silva-Tillmann BA, Mensing S, Podsadecki TJ, Awni WM, Dutta S, Menon RM. Polepally AR, et al. Among authors: mensing s. Antivir Ther. 2016;21(8):707-714. doi: 10.3851/IMP3079. Epub 2016 Sep 1. Antivir Ther. 2016. PMID: 27584548

9

Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.

Mensing S, Eckert D, Sharma S, Polepally AR, Khatri A, Podsadecki TJ, Awni WM, Menon RM, Dutta S. Mensing S, et al. Br J Clin Pharmacol. 2017 Mar;83(3):527-539. doi: 10.1111/bcp.13138. Epub 2016 Nov 3. Br J Clin Pharmacol. 2017. PMID: 27662429 Free PMC article.

10

Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection.

Polepally AR, Wang H, Marroum PJ, Minocha M, Hosmane B, Khatri A, Mensing S, Podsadecki TJ, Cohen DE, Awni WM, Menon RM. Polepally AR, et al. Among authors: mensing s. AAPS J. 2017 Sep;19(5):1523-1535. doi: 10.1208/s12248-017-0115-3. Epub 2017 Jul 6. AAPS J. 2017. PMID: 28685397 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Search Page

Filters